Curtis Keith, PhD

Chief Scientific Officer, Blavatnik Biomedical Accelerator

Curtis joined OTD in 2008. Prior to joining Harvard, Curtis worked at CombinatoRx, Inc., a pioneering company in the emerging field of synergistic combination pharmaceuticals, where he served as co-founder and Senior Vice President, Research. At CombinatoRx, Curtis directed research programs in multiple therapeutic areas, including rheumatoid arthritis, psoriasis, osteoarthritis, oncology, metabolic, neurodegenerative and infectious disease, and helped the company to advance a pipeline of several clinical and preclinical drug candidates. Curtis holds an MA in chemistry and a PhD in chemistry and chemical biology from Harvard University.